Laboratoires d'excellence hors Idex
Référence projet : 11-LABX-0009
RST : Philippe AMOUYEL
Etablissement Coordinateur : Fondation I-SITE Université Lille Nord-Europe
Région du projet : Hauts de France
Discipline : 5 - Bio Med
Aide de l'ANR 8 752 480 euros
Investissement couvrant la période de février 2012 à décembre 2022
DISTALZ aims at promoting a comprehensive view of the Alzheimer’s disease (AD) pathophysiological models, by bringing together a critical mass of geneticists, biologists, clinicians, social and healthcare scientists on a common transdisciplinary agenda.
DISTALZ explores current and new hypotheses involved in the AD pathophysiological process, especially in regard to new genetic findings emerging from genomic research, and derives from this knowledge new biological insights that will be developed as potential biomarkers and putative drug targets. The multidisciplinary approach of DISTALZ allows setting up the biological, clinical, social and ethical bases of clinical trials aimed at recruiting individuals a patients with the highest AD risk, years before any conversion to AD.
The progresses are in line with the proposed agenda and for some aspects, as transdisciplinarity, well beyond the initial expectations. DISTALZ has accelerated the understanding of the genetic susceptibility of AD thanks to the use of whole exon and genome sequencing. A synergic collaboration with amyloid and Tau specialists has allowed to analyze the function of some of the gene loci identified, improving the deciphering of the molecular mechanisms underlying the early phases of the disease through a mechanistic point of view with the help of biophysics. The potential consequences of the identification of new targets for diagnosis, well before any symptom occurred, are anticipated in a clinical and social setting including all different aspects of psychological and ethical impacts, with a specificity in young onset patients and their carers. DISTALZ teams have initiated several local, national and international education programs, engaged several collaborations with two biotech companies and pharma industries and helped to launch a new start-up. Finally, the general public and social commitment of DISTALZ researchers has favored a large dissemination and destigmatization of this terrible threat.
L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.